World journal of surgical oncology · 2026
Serous cystadenocarcinoma of the pancreas: a population-based study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dotevall Theodore, Kolmodin Emelie, Thylefors Ebba, Andersson Roland, Ansari Daniel
Аннотация
BACKGROUND: Serous cystadenocarcinoma (SCAc) of the pancreas is an exceptionally rare malignant pancreatic neoplasm, and its clinical characteristics, treatment patterns, and prognosis remain poorly defined. The aim of this population-based study was to characterize the demographic and clinical features, treatment patterns, and survival of patients with pancreatic SCAc.
METHODS: Patients with microscopically confirmed SCAc were identified from the Surveillance, Epidemiology, and End Results (SEER) registry. Demographic, tumor-related, treatment, and survival data were analyzed using descriptive statistics and Kaplan-Meier survival analysis.
RESULTS: Twenty-one patients with SCAc were identified. Median age at diagnosis was 69 years, and 13 patients (62%) were female. Tumors most frequently involved the pancreatic body or tail. Disease was localized in 4 patients (19%), regional in 6 (29%), distant in 9 (43%), and unstaged in 2 (10%). Surgical resection was performed in 12 patients (57%), and 6 (29%) received chemotherapy. Estimated 5-year overall survival (OS) was 60.5% for the overall cohort. Five-year OS was 73.3% among patients who underwent resection and 44.4% among those who did not.
CONCLUSIONS: Pancreatic SCAc is a rare malignancy with frequent involvement of the pancreatic body or tail. Surgical resection was the most common treatment, whereas chemotherapy was used in a minority of patients. Population-based data suggest relatively favorable long-term survival.
METHODS: Patients with microscopically confirmed SCAc were identified from the Surveillance, Epidemiology, and End Results (SEER) registry. Demographic, tumor-related, treatment, and survival data were analyzed using descriptive statistics and Kaplan-Meier survival analysis.
RESULTS: Twenty-one patients with SCAc were identified. Median age at diagnosis was 69 years, and 13 patients (62%) were female. Tumors most frequently involved the pancreatic body or tail. Disease was localized in 4 patients (19%), regional in 6 (29%), distant in 9 (43%), and unstaged in 2 (10%). Surgical resection was performed in 12 patients (57%), and 6 (29%) received chemotherapy. Estimated 5-year overall survival (OS) was 60.5% for the overall cohort. Five-year OS was 73.3% among patients who underwent resection and 44.4% among those who did not.
CONCLUSIONS: Pancreatic SCAc is a rare malignancy with frequent involvement of the pancreatic body or tail. Surgical resection was the most common treatment, whereas chemotherapy was used in a minority of patients. Population-based data suggest relatively favorable long-term survival.